Mainstream Capital Management LLC Allogene Therapeutics, Inc. Transaction History
Mainstream Capital Management LLC
- $143 Billion
- Q4 2024
A detailed history of Mainstream Capital Management LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Mainstream Capital Management LLC holds 7,450 shares of ALLO stock, worth $12,218. This represents 0.01% of its overall portfolio holdings.
Number of Shares
7,450Holding current value
$12,218% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ALLO
# of Institutions
166Shares Held
134MCall Options Held
59.4KPut Options Held
113K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$30.7 Million1.25% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$27 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.33MShares$13.7 Million0.0% of portfolio
-
State Street Corp Boston, MA7.01MShares$11.5 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$11.3 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $236M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...